2014 Issues   /   February 2014

VA Study Finds Mortality Greater with Some Diabetes Drugs

USM By U.S. Medicine
February 5, 2014

SEATTLE — How do oral hypoglycemic medications for type 2 diabetes affect overall mortality?

Concerned that few studies had been done on the drugs’ comparative safety, researchers from the VA Puget Sound Health Care System in Seattle sought to answer that question. The results, based on a comparison of mortality risk with monotherapy initiation of four oral hypoglycaemic medications in a nationwide cohort of U.S. veterans with type 2 diabetes, were published online recently by the journal Diabetologia.1

“Significantly higher mortality was associated with glibenclamide, glipizide and rosiglitazone use compared with metformin, and with glipizide use compared with rosiglitazone or glibenclamide,” the authors reported, adding that “the potential for residual confounding by indication should be considered in interpreting these results.”

For the study, researchers identified new users of oral hypoglycaemic medication monotherapy between 2004 and 2009 who received care for at least a year at the VHA. Follow-up within the study period continued until patients either ended their initial monotherapy, had an additional diabetes pharmacotherapy added or died.

Results indicated that among new users of metformin sulfonylureas and rosiglitazone representing 185,360 men and 7,812 women, 2.2% (4,256) died during follow-up. Average duration of medication use ranged from 1.4 to 1.7 years.

Study authors pointed out that significantly higher mortality risk was seen for glibenclamide, sold as glyburide in the U.S. and Canada, or glipizide compared with metformin monotherapy. That also was the case with glipizide compared with rosiglitazone or glibenclamide monotherapy.

In the case of rosiglitazone compared with metformin monotherapy, women had a higher risk of death (HR 4.36, 95% CI 1.34, 14.20) than men (HR 1.19, 95% CI 0.95, 1.49).

Study authors called for more research on the comparative safety of commonly employed diabetes drugs.

1.Wheeler S, Moore K, Forsberg CW, Riley K, Floyd JS, Smith NL, Boyko EJ.

Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy. Diabetologia. 2013 Jun 25. [Epub ahead of print]PubMed PMID: 23797633.

Related Articles

Fibromyalgia Presents Differently in Male, Female Veterans

Research on fibromyalgia, a poorly understood, chronically disabling pain syndrome, generally has focused on its clinical presentation and treatment.

How Veterans Feel About Remote Management of Their Care

The VA is expanding remote management of patients to improve disease prevention and care.

U.S. Medicine Recommends

More From department of defense dod

Department of Defense (DoD)

High Rate of Pectoralis Tears Among Deployed Servicemembers Lifting Weights

Lifting weights is one way servicemembers keep in peak physical condition during deployment.

Department of Defense (DoD)

DoD Study Finds That Type 2 Diabetes Increases Breast Cancer Mortality

Having Type 2 diabetes mellitus (DM-2) increases mortality risk in breast cancer patients, regardless of whether diabetes was diagnosed before or after breast cancer, according to a recent study.

Department of Defense (DoD)

Now Hear This: Otolaryngologist Leads Effort to Prevent Auditory Issues

Among those who are exposed to combat, it’s the weapons fire that does it. In the Navy, it’s the noise levels in engine rooms and on the decks of carriers.

Department of Defense (DoD)

GAO: ‘Gaps’ in MHS Physician Specialties Could Affect Wartime Readiness

WASHINGTON — The military services need to develop “targeted and coordinated strategies” to alleviate military physician gaps, a recent report recommended.

Department of Veterans Affairs (VA)

VA Vows to Meet Deadline for Revamp of Veteran Claims Appeal Process

WASHINGTON—VA has told legislators that the agency is on track with a new law that will give veterans more options to have their claims appeals reviewed.

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up